drugset
drugset / Trial / NCT00884182

Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children

NCT00884182 ↗

Phase 2 Completed 350 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupOpen-labelPrevention

Summary

This study is part of an effort to develop an effective vaccination program in children in the event of a pandemic. Study objectives: * To describe the safety profiles in the periods following each vaccination in subjects receiving different vaccination schedule. * To describe the immune response after each vaccination in subjects receiving study vaccine.

Timeline

Start
2009-04
Primary completion
2010-03
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine Vaccine 0.5 ml Intramuscular

Indications

influenza